UCB (OTCMKTS:UCBJY) Raised to “Strong-Buy” at Zacks Research

UCB (OTCMKTS:UCBJY) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

A number of other research firms also recently weighed in on UCBJY. Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a research note on Monday. Barclays cut UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy”.

UCB Stock Performance

OTCMKTS UCBJY opened at $132.20 on Tuesday. UCB has a 12 month low of $106.24 and a 12 month high of $168.76. The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20. The company has a 50-day moving average of $142.79 and a 200-day moving average of $146.99.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.